Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V503 (Gardasil 9) and Repevax Co-administration in Adolescents
NCT01073293Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2010
- Primary completion
- Jun 2011
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by Merck & Co.. Started Apr 2010; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT01073293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01073293.